Actionable news
0
All posts from Actionable news
Actionable news in ETRM: EnteroMedics Inc.,

vBloc® Therapy Data Demonstrate Two Year Maintenance of Clinically Significant Weight Loss and Sustained Improvements in Obesity Related Risk Factors

EnteroMedics Announces Chief Medical Officer, Scott A. Shikora, M.D., F.A.C.S., Awarded 2015 Outstanding Achievement Award from ASMBS
Results and Award Presented at Obesity Week, November 2-6, 2015

ST. PAUL, Minn., Nov. 4, 2015 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the presentation of two year follow up results from the ReCharge Study of vBloc Neurometabolic Therapy in obesity. The results were presented in two abstracts at Obesity Week 2015, a joint Annual Meeting of the American Society of Metabolic and Bariatric Surgery and The Obesity Society taking place in Los Angeles November 2-6, 2015.

"Among the major challenges with obesity treatment are maintaining weight loss over time and avoiding the health risks associated with weight gain and cycling," said Scott Shikora M.D. F.A.C.S, EnteroMedics Executive Vice President and Chief Medical Officer. "At the two-year follow-up, data from the ReCharge Trial demonstrate that intermittent vagal blocking provides maintenance of clinically significant weight loss and a continued favorable safety profile. These data also demonstrate meaningful and sustained reduction in measures of cardiovascular risk factors, improvements in indicators of pre-diabetes and metabolic syndrome, as well as improvements in weight-related quality of life and eating behaviors, pointing to vBloc as a safe and effective long-term weight loss solution."

The Company also announced that Dr. Shikora was awarded the 2015 Outstanding Achievement Award from the American Society of Metabolic and Bariatric Surgery (ASMBS). The ASMBS Foundation's Outstanding Achievement Award honors an ASMBS member who supports the goals and vision of the ASMBS Foundation, has displayed a lasting impression and selfless commitment to the ASMBS organization and has made significant contributions to the field of metabolic and bariatric surgery.

Weight Loss at 24 Months

The ReCharge pivotal trial is a prospective double-blind, sham-controlled clinical trial of vBloc Neurometabolic Therapy for the treatment of obesity. The trial includes 239 randomized (2:1) patients with a BMI of 40-45kg/m2 or 35-40 kg/m2 with at least one obesity-related condition(s). The double-blind period of the ReCharge Trial has been completed and the trial has transitioned to a 5-year, open-label study of the safety and effectiveness of vagal blocking.

Percent excess weight loss (EWL), percent total body weight loss...


More